Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Rosenbaum

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Clinical and Experimental Gastroenterology|April 15, 2024
An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with ConstipationPrashant Singh, Gregory S Sayuk, David P Rosenbaum, et al.
Clinical Pharmacology in Drug Development|March 17, 2017
Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug InteractionsSusanne Johansson, David P Rosenbaum, Marie Ahlqvist, et al.
Journal of Neurosurgery. Pediatrics|January 4, 2011
Posterior fossa craniotomy for trapped fourth ventricle in shunt-treated hydrocephalic children: long-term outcomeSuhas Udayakumaran, Naresh Biyani, David P Rosenbaum, et al.
Clinical and Experimental Gastroenterology|August 8, 2024
Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United StatesMorgan Allyn Sendzischew Shane, Johannah Ruddy, Michael Cline, et al.
Therapeutic Advances in Gastroenterology|April 11, 2024
Long-term safety of tenapanor in people with irritable bowel syndrome with constipation from the T3MPO-3 study: plain language summary of publicationAnthony J Lembo, Susan Edelstein, David P Rosenbaum, et al.
British Journal of Clinical Pharmacology|April 23, 2017
Tenapanor administration and the activity of the H<sup>+</sup> -coupled transporter PepT1 in healthy volunteersSusanne Johansson, David P Rosenbaum, Johan Palm, et al.
Therapeutic Advances in Gastroenterology|January 28, 2026
Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysisBrian E Lacy, Andrea S Shin, David J Cangemi, et al.
Current Medical Research and Opinion|July 23, 2024
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE studyStuart M Sprague, Susan Edelstein, David M Spiegel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 5, 2018
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemiaGeoffrey A Block, David P Rosenbaum, Andrew Yan, et al.
Nephrology Nursing Journal : Journal of the American Nephrology Nurses' Association|July 7, 2025
The Positive Impact of Patient Education on Tenapanor Adherence in the OPTIMIZE StudyRory C Pace, David P Tietjen, David M Spiegel, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Gastroenterology|April 15, 2024
An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with ConstipationPrashant Singh, Gregory S Sayuk, David P Rosenbaum, et al.
Clinical Pharmacology in Drug Development|March 17, 2017
Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug InteractionsSusanne Johansson, David P Rosenbaum, Marie Ahlqvist, et al.
Journal of Neurosurgery. Pediatrics|January 4, 2011
Posterior fossa craniotomy for trapped fourth ventricle in shunt-treated hydrocephalic children: long-term outcomeSuhas Udayakumaran, Naresh Biyani, David P Rosenbaum, et al.
Clinical and Experimental Gastroenterology|August 8, 2024
Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United StatesMorgan Allyn Sendzischew Shane, Johannah Ruddy, Michael Cline, et al.
Therapeutic Advances in Gastroenterology|April 11, 2024
Long-term safety of tenapanor in people with irritable bowel syndrome with constipation from the T3MPO-3 study: plain language summary of publicationAnthony J Lembo, Susan Edelstein, David P Rosenbaum, et al.
British Journal of Clinical Pharmacology|April 23, 2017
Tenapanor administration and the activity of the H<sup>+</sup> -coupled transporter PepT1 in healthy volunteersSusanne Johansson, David P Rosenbaum, Johan Palm, et al.
Therapeutic Advances in Gastroenterology|January 28, 2026
Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysisBrian E Lacy, Andrea S Shin, David J Cangemi, et al.
Current Medical Research and Opinion|July 23, 2024
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE studyStuart M Sprague, Susan Edelstein, David M Spiegel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 5, 2018
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemiaGeoffrey A Block, David P Rosenbaum, Andrew Yan, et al.
Nephrology Nursing Journal : Journal of the American Nephrology Nurses' Association|July 7, 2025
The Positive Impact of Patient Education on Tenapanor Adherence in the OPTIMIZE StudyRory C Pace, David P Tietjen, David M Spiegel, et al.
Pageof 4